The APCCC in Basel, Switzerland: Day 1

So in this series of reports on what happened at the 3rd Advanced Prostate Cancer Consensus Conference (APCCC) in Basel, Switzerland, we will not be trying to get into detail about exactly what data got presented each day. … READ MORE …

Radio-guided surgery in the treatment of recurrent, initially localized prostate cancer

The re-treatment of patients with recurrent prostate cancer after initial, first-line treatment for what was initially diagnosed as localized disease can be complicated. Success (i.e., effective re-treatment with curative intent) in the re-treatment of such patients is often dependent on the ability to identify exactly where recurrence has occurred. … READ MORE …

ADT + bevacizumab as first-line treatment of recurrent prostate cancer

Data from a small, randomized, Phase II, clinical trial have suggested a possible role for bevacizumab (Avastin) in the treatment of men with recurrent prostate cancer along with androgen deprivation therapy (ADT). … READ MORE …

White button mushroom powder and recurrent prostate cancer

A small Phase I clinical trial in just 36 patients, funded by the Mushroom Growers of Australia and North America, has suggested that powdered mushroom may have an effect on PSA levels of at least some men with recurrent prostate cancer after first-line therapy. … READ MORE …

Gallium-68 PSMA as an imaging agent in prostate cancer recurrence

A report in the Journal of Nuclear Medicine suggests that gallium-68 PSMA (68Ga-PSMA or [68Ga]PSMA) is better than an older radionuclide in detecting recurrent lesions in men with progressive prostate cancer after first-line therapy with surgery or radiation therapy. … READ MORE …

INO-5150 enters initial clinical trials

Inovio Pharmaceuticals is initiating a Phase I trial of INO-5150 — a new type of immunotherapy for prostate cancer which targets both the prostate-specific antigen (PSA) and the and the prostate specific membrane antigen (PSMA). … READ MORE …

Salvage treatment of recurrent, lymph node-positive prostate cancer in the modern era

The advent of imaging tests like the [11C]choline PET/CT scan and others have made it possible to identify, relatively early, the presence of one or more foci of recurrent prostate cancer after first-line therapy, and often these recurrent foci can be found in patients’ pelvic lymph nodes. … READ MORE …

Current and future imaging techniques and recurrent prostate cancer

An article just reproduced on the Medscape Oncology web site provides a very readable review of what the authors describe as, “A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer”. … READ MORE …

Potential of metformin in management of recurrent/progressive prostate cancer

A newly published, retrospective, epidemiological study has looked at the potential role of metformin the the management of prostate cancer in > 350 men already diagnosed and being treated for diabetes in the Shared Equal Access Regional Cancer Hospital (SEARCH) database. … READ MORE …

Newer radio-tracer shows potential in imaging of recurrent prostate cancer

Data have been emerging for a while to suggest that a new imaging agent known as anti-3-[18F]FACBC (when used in PET/CT scans may be better than [11C]choline in the identification of recurrent (or primary) cancers on PET/CT scans or than older agents like [111In]capromab pendetide (Prostascint) when used in SPECT/CT scans. … READ MORE …

PET/MRI vs. PET/CT in restaging of recurrent prostate cancer

A study presented this week at the annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in Vancouver compares [11C]choline-enhanced PET/CT and PET/MRI scanning in men with recurrent prostate cancer. … READ MORE …

For our “natural therapy” adherents from the GU Cancers Symposium

There were two posters presented at the Genitourinary Cancers Symposium regarding the use of “natural” agents in the management of prostate cancer. … READ MORE …

More on [11C]choline PET/CT scanning in men with recurrent prostate cancer

A new article just published on line in the Journal of Urology offers additional information about the “operational characteristics” of [11C]choline PET/CT scanning in the diagnosis of biochemically recurrent prostate cancer after first-line treatment (a technique currently available only at the Mayo Clinic in Rochester, MN). … READ MORE …

FDA approves specialized imaging agent for PET scans in recurrent prostate cancer

The  U.S. Food & Drug Administration (FDA), yesterday, approved an imaging agent known as Choline C11 Injection for “production and use” to detect recurrent prostate cancer in men receiving positron emission tomongraphy or PET scanning. … READ MORE …

University of Iowa starts Phase II trials with Ad/PSA vaccine

A research team at the University of Iowa is seeking patients to enroll in Phase II clinical trials of a new form of vaccine immunotherapeutic to treat men with recurrent prostate cancer. … READ MORE …